Why GLP-1 spend breaks a mid market pharmacy benefit
Upgrades Health · August 12, 2026 · 5 minute read
A pharmacy benefit for a company with 80 employees was designed around a simple assumption: expensive drugs are rare. A specialty claim shows up occasionally, the pool absorbs it, and the plan moves on. GLP-1s break that assumption, because this time the expensive drug is one a large share of the workforce qualifies for.
The assumption underneath every mid market plan
Small group and mid market pharmacy benefits are priced on spread risk across a small pool. The model tolerates one or two outlier claims. It does not tolerate a standing, recurring, monthly claim that many members are eligible for at once. That is not a failure of any one carrier. It is what happens when a drug category built for chronic use meets a plan built for episodic cost.
A national employer has levers when this happens. It can renegotiate, self fund, carve out categories, or use its size to demand pricing concessions. A company with 80 employees has almost none of those levers. It gets the renewal letter.
Where the money actually goes
When a GLP-1 claim runs through a conventional pharmacy benefit, the amount the employer pays and the amount the pharmacy receives are not the same number. The difference is spread, and in most mid market arrangements nobody at the employer ever sees it. Add rebate flows that route through intermediaries, and the true unit cost of the medication becomes very hard for a CFO to state with confidence.
That opacity is tolerable when the category is small. When the category becomes one of the largest lines in the plan, opacity is the problem. You cannot manage a number you cannot see.
The plan was built for a world where the expensive drug is rare. GLP-1s made the expensive drug common.
The three responses employers reach for first
Most employers try one of three things before considering a structural change.
- Exclusion. Drop coverage for weight management GLP-1s entirely. It works on the spreadsheet and fails everywhere else. Employees who need the medication notice, and the benefit becomes a recruiting liability instead of an asset.
- Utilization management. Prior authorization, step therapy, reauthorization cycles. This slows spend without controlling unit cost, and it pushes the administrative burden onto employees and their doctors.
- Cost shifting. Raise the copay tier until the employee carries most of the cost. In practice this quietly converts coverage into non coverage for anyone without disposable income, which defeats the point of offering the benefit.
Each of these treats the symptom, which is utilization, instead of the structure, which is pricing the employer cannot see or negotiate.
The structural alternative
The fourth option is to move the category out of the carrier pharmacy benefit entirely. Weight management GLP-1s come off the carrier formulary, and the employer runs them through a directed program with one fixed monthly price per member and documented U.S. pharmacy sourcing. Licensed prescribers. Clear standards. A different chassis underneath.
Structurally, the change does three things. It makes the unit cost a known, fixed number instead of an output of an opaque arrangement. It removes intermediary spread from the category. And it puts the employer in control of plan design decisions for the one category most likely to dominate the next renewal.
What the carve out does not do on its own is take care of the clinical side. Somebody still has to evaluate each employee, decide whether therapy is appropriate, monitor progress, and manage dosing over time. A program that solves pricing and skips that part has moved the problem, not solved it. We have written about that separately, because it deserves its own argument.
What to take to your broker
If GLP-1 spend is climbing in your plan, ask your broker two questions. What is the true per fill cost of this category in our current arrangement, and can anyone show it to us in writing? And second, what would this category cost in a directed program with fixed monthly pricing? The gap between those two answers is the size of the decision in front of you.
The employers who handle this well are not the ones who move fastest. They are the ones who insist on seeing both numbers before renewal season makes the choice for them.
